← Back to patent-cliff list
Celecoxib/Tramadol Hydrochloride
Tier C — Watch / tradeCelecoxib/Tramadol Hydrochloride
Esteve Pharmaceuticals LLC
Originator
2021
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：COX-2, MOR1
Indications (approved)：急性疼痛
Regional status
US
Approved
2021-10-15
EU
-
China
IND filed
2017-07-31
Japan
-
Factories producing this API9
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
9 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Celecoxib/Tramadol Hydrochloride?
Approved indications include: 急性疼痛.
When does the Celecoxib/Tramadol Hydrochloride patent expire?
No public expiry year is available for Celecoxib/Tramadol Hydrochloride yet; this page updates once verified.
How do I get a quote for Celecoxib/Tramadol Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27